SOLICITATION NOTICE
66 -- Acquisition of a BD Bioscience Accuri C6 Plus system
- Notice Date
- 8/22/2016
- Notice Type
- Presolicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02RC62675-76
- Archive Date
- 9/1/2016
- Point of Contact
- Catherine Muir, Phone: (240) 276-5434
- E-Mail Address
-
muirca@mail.nih.gov
(muirca@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address: Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E144, Bethesda, MD 20892, UNITED STATES Description: The National Cancer Institute (NCI), Center of Cancer Research (CCR), Laboratory of Genome Integrity (LGI), T cell Biology and Development Unit, plans to procure, on a sole source basis, a BD Accuri C6 Plus system by BD Biosciences, One Becton Drive, Franklin Lakes, NJ 07417. The response close date of this notice for this requirement is in accordance with FAR 5.203(a)(1). This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1) and is exempt from the requirements of FAR Part 6. The North American Industry Classification System (NAICS) code is 334516 and the business size standard is 1,000 employees. Only one (1) award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The period of performance: delivery will be within 90 days from date of award. It has been determined there are no opportunities to acquire green products or services for this procurement. The research program in the Laboratory of Genome Integrity is focused on the exploration of the causes and effects of genomic instability, mechanisms of DNA repair and the study of DNA repair breakdown as an initiating or protective event in aging and cancers. The program will emphasize a mechanistic understanding of the pathways that maintain genomic integrity, the intersection of these pathways with normal cellular physiology and cancer and the application of these insights to the development of new therapeutic strategies. The laboratory has made major contributions towards a detailed understanding of DNA repair pathway selection as a primary influence on genomic stability and drug resistance/sensitivity in breast and ovarian cancers and the influential role of DNA repair proteins in the promotion of specific hematological malignancies. The Laboratory is also expanding its efforts in the areas of cellular identity and development by examining the differentiation of hematopoietic stem cells into early T-cell lineage progenitors. This new program will place particular importance towards a comprehensive understanding of the cellular signals that influence hematopoietic progenitor migration, the transcription factors that positively and negatively impact T-cell lineage selection and the contribution of deregulated normal developmental processes in T-cell aging and cancer. The Laboratory of Genome Integrity also manages a state-of-the-art flow cytometry core that houses four cell sorters, four cell analyzers and serves the scientific needs of over 200 scientists and 80 different principal investigators every year. This facility will continue to provide both routine as well as highly specialized sorting services to members of the CCR-NCI community. The National Cancer Institute (NCI), Center for Cancer Research (CCR), Laboratory of Genetics Integrity (LGI), the T cell Biology and Development Unit within the Laboratory of Genome Integrity relies on cell counting for all experiments. The traditional manual cell counting method using a hemocytometer are slow and inaccurate. The preparation of slide for counting each sample is time intensive and laborious. Additionally, manual cell counts can be affected by many parameters, such as the origin and quality of the tissue, the experimenter or sample features such as cell concentration. Obtaining accurate cell counts of thymocytes and bone marrow cells are fundamental to a better understanding of the T cell developmental paradigm being elaborated in the LGI. Highly precise cell number measurements are a critical experimental measure and serve as the principal basis in the calculation of absolute numbers of developing cell subsets during cellular development. As importantly, all downstream experimentation is heavily reliant on these initial cell counts. The Contractor shall provide the following specifications/characteristics that are required include: • A small footprint with fluid bottles and a weight under 35 lbs, No specialized housing considerations need to be employed. • Absolute cell counts can be obtained without the need to add counting beads or the use of any additional testing equipment or reagents. • No air-over-fluid pressure is needed to create hydrodynamic focusing of the sheath. • Many sample tube types can be used including 12 x 75 mm tubes, and various microcentrifuge tubes. Importantly, microcentrifuge tubes can be used for sample volumes as low as 50μl. • Capable of acquiring data at event rates up to 10,000 events/sec. A wide range of flow rates, continuously variable from 10-100 μl and core sizes variable from 5-40 μm allow for increased resolution and speed in data collection. • Allows two low powered lasers to be used for fluorochrome excitation (14.7 mW 640 nm Diode Red Laser and 20 mW 488 nm Solid State Blue Laser), and 4 detectors for fluorochorome emission (533/30, 585/40, LP670, and 675/25 nm). This allows for the simultaneous detection and analysis of the 4 most commonly used fluorochromes in addition of the light scatter necessary for cell counting. • A 24-bit digital signal processor generates data over a range of 7.2 decades or 16,000,000+ channels and the Zoom function allows focusing on populations of interest, eliminating the need to make voltage adjustments to the detectors. This, in turn, allows for easier data collection as reducing sample waste when setting up new applications. Endogenous autofluorescence or extremely bright signals necessitate voltage adjustments on other flow cytometers in order to collect data on-scale. The wide dynamic range of the C6 allows both dim and bright signals to be displayed on the same scale. Pre-optimized and set voltage and gain settings, also enhance reproducibility of results, and comparability to data from other C6s, e,g, during collaboration. • Start up and shut down are fully automatized for gain of time and reliability. • Routine maintenance and calibration is easily performed by the user. The replacement of the inline sheath fluid filter, fluidics bottle filters and peristaltic pump tubing every two months takes less than fifteen minutes with a reasonable annual cost. This is substantially less than other flow cytometer maintenance costs and requires no specialized training. • The sheath fluid recommended for the C6 is filtered, deionized laboratory grade water. • Extended warranty costs are the lowest of any flow cytometer. • Analysis software can be used for data analysis on both a PC or on a Mac without the purchase of software licenses. Sample data can also be exported to third party software including FlowJo, FCS Express, WinList, etc. BD Biosciences is the only known company capable of providing the required scientific equipment including: a) installation; b) technical support and training by the original equipment manufacturer for their equipment, and c) an original equipment manufacturer one (1) year warranty in aggregate. The T cell Biology and Development Unit requires the purchase of hardware and software to quantify cell concentrations in a broad range of cell type and tissue samples. Flow cytometry based cell counting proposed by the Accuri C6 Plus system is the most accurate, time saving and fiscally prudent way to count cells. Becton Dickinson is the only known company that can provide the hardware and software to perform these services, and offering the aforementioned combination of features that the LGI requires. This notice is not a request for competitive quotation. However, if any interested party, especially small businesses, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 3:30PM EDT, on Aug. 6, 31, 2016. All responses and questions must be in writing and faxed (240) 276-5401 or emailed to Catherine Muir, Contracting Officer via electronic mail at muirca@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, Contractors must be registered and have valid, current Entity Record, including current Representations and Certifications, in the System for Award Management (SAM) through SAM.gov. Reference: N02RC62675-76 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02RC62675-76/listing.html)
- Record
- SN04234940-W 20160824/160822235358-13bc0f7b94399e30ad31b3c09a9f17e7 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |